To the editor,

Many thanks to Professor Klara Rosta, M.D., Ph.D., Gábor Firneisz, M.D., Ph.D., *et al.* for their interest on our recently published article, 'A functional polymorphism rs10830963 in melatonin receptor1B associated with the risk of gestational diabetes mellitus' \[[@B1]\] and appreciate their comments \[[@B2]\] on it. We believe that peer exchanges among different research groups can promote better research works.

In the recent study, according to 14 reported research data on the association between a functional polymorphism rs10830963 in *MTNR1B* gene and the risk of gestational diabetes mellitus, we performed a meta-analysis by using Stata software, version 12.0 (Stata Corp LP, College Station, TX, U.S.A.) \[[@B3],[@B4]\]. The false positive report probability (FPRP) analyses were adopted to confirm the positive findings \[[@B5],[@B6]\]. Klara Rosta, M.D., Ph.D., *et al.* paid attention to one included study (good works from Rosta *et al.*, 2017) in this meta-analysis, then put forward some opinions and suggestions on the minor (rs10830963 G) allele frequencies (MAF), the calculation of effect value (odds ratios, ORs) and the indication of relevant clinical data (mean age and pre-pregnancy BMI). We are here to respond. If there are any inaccuracies in our response, we welcome to communicate again.

Since we read the original literature of Rosta *et al.*, 2017 \[[@B7]\], we found that not the exact genotyping data but an MAF of each studied SNP locus, including rs10830963 was reported. Therefore, we can not extract the accurate sample size data of being successfully genotyped. According to the number of 287 GDM cases meet the International Association of the Diabetes and Pregnancy Study Group (IADPSG) criteria and 533 controls reported in the literature, we estimated the genotype data by using the Hardy--Weinberg equilibrium (HWE) genotype distributions. The approach is recognized. As reminded by the commentary, we have carefully verified the extraction MAF in the literature, and hereby we correct it and other relevant research data.

We recalculate the results using the new genotype data, and the association between the SNP rs10830963 and the risk of GDM is still confirmed ([Figures 1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"}). Further functional experimental studies are warranted to explore and clarify the potential mechanism. Meanwhile, the variant rs10830963 G allele was estimated significantly associated with an increased GDM risk (CG vs. CC: OR = 1.44, 95% CI = 1.06−1.95; GG vs. CC: OR = 2.06, 95% CI = 1.26−3.37; G vs. C: OR = 1.44, 95% CI = 1.16−1.78) in the meta-analysis for Rosta *et al.*'s study data ([Figures 1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"}). There are slightly different of OR and corresponding 95% CI from the original literature. Maybe it was caused by meta-analysis process for different algorithms with stata software.
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In epidemiological research, it is necessary to clarify the general demographic characteristics, and we have also carried out extraction and display in [Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}. For the mean pre-pregnancy body mass index (BMI) and mean age values with the subjects, we have re-extracted and supplemented in the [Table 1](#T1){ref-type="table"}. The mean age of cases/controls were 32.04/30.51 in subjects of Austria and 33.70/31.25 of Hungary. Meanwhile, the mean BMI of cases/controls were 28.31/23.40 in Austria and 26.78/23.32 in Hungary ([Table 1](#T1){ref-type="table"}).

###### Characteristics of the studies included in the meta-analysis

  Author, year          Country               Diagnostic criteria   Genotyping methods      Controls           Number of case/control   MAF case/control   Mean age of cases/controls                 Mean BMI of cases/controls                 *P*~HWE~ for controls   NOS score
  --------------------- --------------------- --------------------- ----------------------- ------------------ ------------------------ ------------------ ------------------------------------------ ------------------------------------------ ----------------------- -----------
  Deng Z., 2011         China                 ADA                   Sequencing              NGT                87/91                    0.52/0.41          31.8 ± 4.6/29.7 ± 3.5                      23.6 ± 3.0/21.5 ± 2.4                      0.84                    4
  Kim J.Y., 2011        Korea                 ADA                   TaqMan                  NGT                908/966                  0.52/0.45          33.1/32.2                                  23.3 ± 4.0/21.4 ± 2.9                      0.53                    7
  Wang Y., 2011         China                 ADA                   TaqMan                  NGT                700/1029                 0.46/0.43          30.0/32.0                                  21.5/21.7                                  0.81                    8
  Vlassi M., 2012       Greece                ADA                   PCR-RFLP                NGT                77/98                    0.41/0.28          35.4 ± 4.4/31.3 ± 5.2                      25.8 ± 5.1/26.7 ± 6.2                      0.02                    4
  Huopio H., 2013       Finland               ADA                   Sequenom Assay/TaqMan   NGT                533/407                  0.47/0.35          32.6/29.9                                  26.3 ± 4.7/24.1 ± 3.8                      0.98                    8
  Li C., 2013           China                 IADPSG                PCR-RFLP                NGT                350/480                  0.45/0.40          32.4 ± 4.8/31.9 ± 5.2                      25.3 ± 5.2/24.6 ± 4.6                      0.79                    8
  Qi J., 2013           China                 IADPSG                Sequencing              NGT                110/110                  0.54/0.44          28.7 ± 3.1/28.1 ± 2.4                      NA/NA                                      0.43                    6
  Vejrazkova D., 2014   Czech                 WHO                   TaqMan                  NGT                458/422                  0.38/0.29          34.1 ± 6.1/34.8 ± 15.1                     24.3 ± 4.9/23.7 ± 4.2                      0.48                    8
  Wang X., 2014         China                 ADA                   PCR-RFLP                NGT                184/235                  0.42/0.45          28.2 ± 3.8/27.9 ± 4.1                      21.2 ± 1.8/20.7 ± 1.4                      0.53                    6
  Junior J.P., 2015     Brazil                ADA                   real-time PCR           Healthy pregnant   183/183                  0.28/0.20          32/29                                      32.0/25.4                                  0.11                    7
  Liu Q., 2015          China                 ADA                   TaqMan                  NGT                674/674                  0.51/0.44          31.6/32.1                                  24.4/25.2                                  0.02                    8
  Tarnowski M., 2017    Poland                IADPSG                TaqMan                  NGT                204/207                  0.39/0.31          31.7 ± 4.5/29.2 ± 5.0                      25.1 ± 5.5/23.0 ± 4.0                      0.112                   7
  Popova P.V., 2017     Russia                ADA                   RT-PCR                  Healthy pregnant   278/179                  0.35/0.31          31.8 ± 4.8/29.4 ± 4.8                      25.7 ± 5.9/22.9 ± 4.5                      0.426                   6
  Rosta K., 2017        Hungary and Austria   IADPSG                KASP assay              Healthy pregnant   287/533                  0.36/0.28          Hungary:33.70/31.25; Austria:32.04/30.51   Hungary:26.78/23.32; Austria:28.31/23.40   0.989                   5

Abbreviations: ADA, American Diabetes Association; NGT, normal glucose tolerance; NOS, Newcastle--Ottawa Scale.

###### Meta-analysis of the *MTNR1B* rs10830963 polymorphism on GDM risk

  Subgroup    Heterozygous (CG vs. CC)   Homozygous (GG vs. CC)   Allele mogel (G vs. C)                                                                                                   
  ----------- -------------------------- ------------------------ ------------------------ --------- ---- ----------- ------------------- --------- ---- ------------- ------------------- ---------
  Overall     14                         3952/4736                1.29 (1.16--1.44)        \<0.001   14   2628/2966   1.88 (1.55--2.27)   \<0.001   14   10066/11228   1.37 (1.25--1.50)   \<0.001
  Ethnicity                                                                                                                                                                                
  Asian       7                          2271/2916                1.15 (1.02--1.28)        0.020     7    1543/1796   1.52 (1.23--1.89)   \<0.001   7    6026/7170     1.23 (1.10--1.37)   \<0.001
  Caucasian   7                          1681/1820                1.50 (1.31--1.72)        \<0.001   7    1085/1170   2.45 (1.99--3.02)   \<0.001   7    4040/4058     1.55 (1.41--1.71)   \<0.001

###### FPRP analysis for the significant associations of the *MTNR1B* rs10830963 C\>G polymorphism and GDM risk

                  OR (95%CI)          Prior probability                                   
  --------------- ------------------- ------------------- ------- ------- ------- ------- -------
  **Overall**                                                                             
  CG vs. CC       1.29 (1.16--1.44)   0.002               0.005   0.056   0.375   0.857   0.984
  GG vs. CC       1.88 (1.55--2.27)   0.002               0.007   0.070   0.433   0.884   0.987
  G vs. C         1.37 (1.25--1.50)   0.001               0.004   0.038   0.286   0.800   0.976
  **Asian**                                                                               
  CG vs. CC       1.15 (1.02--1.28)   0.057               0.153   0.664   0.952   0.995   1.000
  GG vs. CC       1.52 (1.23--1.89)   0.003               0.009   0.092   0.506   0.911   0.990
  G vs. C         1.23 (1.10--1.37)   0.003               0.010   0.097   0.519   0.915   0.991
  **Caucasian**                                                                           
  CG vs. CC       1.50 (1.31--1.72)   0.002               0.007   0.074   0.446   0.889   0.988
  GG vs. CC       2.45 (1.99--3.02)   0.016               0.047   0.351   0.845   0.982   0.998
  G vs. C         1.55 (1.41--1.71)   0.002               0.005   0.056   0.375   0.857   0.984

Thank you very much again for Klara Rosta, M.D., Ph.D., Gábor Firneisz, M.D., Ph.D., *et al*.'s thoughtfulness and preciseness. Your comments means a great deal to us. Next, we will improve our study work together with the editors of '*Bioscience Reports*'.
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